2025 AEP Insight: MA Only / MAPD Overview📊

2025 MAPD and MA only plans: Growth in new plans despite market consolidation

October 21, 2024 Market Research

Renewal Plans with SAR increased from 8% to 18% in MA Only plans and from 3% to 11% in MAPD plans.

In 2025, the Medicare Advantage Prescription Drug (MAPD) segment shows a slight decline in the total number of plans, dropping from 5,321 in 2024 to 5,200—a decrease of approximately 2.3%. This reflects a continuation of the slowing growth rate seen in previous years. For MA Only plans, the downward trajectory is even more pronounced. The total number of plans decreased marginally from 484 in 2024 to 482 in 2025, indicating a YoY decline of less than 1%. Despite overall market consolidation, a notable increase was observed in the inclusion of new plans, with MA Only plans rising by 32% YoY and MAPD new plans by 12% YoY in 2025.

The same trend holds across both, MA Only and MAPD plans, with Renewal Plans continuing to have the largest share, though they dropped from 64% to 59% in MA Only and from 65% to 60% in MAPD. Renewal Plans with SAE experienced a sharp decline, particularly in MAPD (13% to 9%) and MA Only (17% to 11%). On the other hand, New Plans showed an uptick, signifying renewed innovation, with MA Only increasing from 7% to 10% and MAPD from 12% to 13%.